Halozyme Therapeutics (MIL:1HALO) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1HALO Halozyme Therapeutics Inc MIL:1HALO
74 GF Score
Price €65.92
GF Value €80.24
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Halozyme Therapeutics FFO?

FFO (Funds from operations) only applies to REITs.

MIL:1HALO
74GF Score
Halozyme Therapeutics Inc MIL:1HALO
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Halozyme Therapeutics (MIL:1HALO) Overvalued in 2026?

Based on GuruFocus' analysis, Halozyme Therapeutics stock appears to be undervalued. The current stock price of €65.92 is trading 17.8% below its estimated GF Value™ of €80.24. GuruFocus considers Halozyme Therapeutics to be Modestly Undervalued.

Key valuation signals for MIL:1HALO:

  • FFO:
  • GF Value™: €80.24 vs. price of €65.92 (17.8% below fair value)
  • GF Score™: 74/100 with 3 warning signs

No single metric tells the full story. See the MIL:1HALO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Halozyme Therapeutics Business Description

Address 12390 El Camino Real, San Diego, CA, USA, 92130
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
74GF Score

Get the complete analysis for MIL:1HALO

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.92
Price
€80.24
GF Value